| Identification | Back Directory | [Name]
Cdc7-IN-5 | [CAS]
1402057-86-6 | [Synonyms]
Cdc7-IN-5
Cdc7IN5,Cdc7 IN 5,Cdc-7-IN-5
3-Furancarboxylic acid, 2-(3,4-dihydro-7-methoxy-2(1H)-isoquinolinyl)-4,5-dihydro-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, ethyl ester | [Molecular Formula]
C25H23N3O5 | [MDL Number]
MFCD34179483 | [MOL File]
1402057-86-6.mol | [Molecular Weight]
445.47 |
| Chemical Properties | Back Directory | [density ]
1.400±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 12.5 mg/mL (28.06 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
12.52±0.40(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle[1]. | [References]
[1] Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|